164 related articles for article (PubMed ID: 30066805)
1. Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan.
Mondini G; Braga PE; Lopes MH; Sartori AMC; Miyaji KT; Infante V; Randi BA; Timenetsky MDCST; Ferreira JCOA; Sakita NK; Precioso AR
Rev Inst Med Trop Sao Paulo; 2018 Jul; 60():e37. PubMed ID: 30066805
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
Vanni T; da Graça Salomão M; Viscondi JYK; Braga PE; da Silva A; de Oliveira Piorelli R; do Prado Santos J; Gattás VL; Lucchesi MBB; de Oliveira MMM; Koike ME; Campos LMA; Coelho EB; Weckx LY; Lara AN; Paiva TM; Timenetsky MDCST; Precioso AR
Vaccine; 2023 May; 41(22):3454-3460. PubMed ID: 37121800
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
Zerbini CA; Ribeiro Dos Santos R; Jose Nunes M; Soni J; Li P; Jain VK; Ofori-Anyinam O
Braz J Infect Dis; 2017; 21(1):63-70. PubMed ID: 27912069
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J
Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
[TBL] [Abstract][Full Text] [Related]
8. Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.
Garg N; Tellier G; Vale N; Kluge J; Portman JL; Markowska A; Tussey L
PLoS One; 2024; 19(6):e0303450. PubMed ID: 38843267
[TBL] [Abstract][Full Text] [Related]
9. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
[TBL] [Abstract][Full Text] [Related]
10. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.
Vajo Z; Tamas F; Jankovics I
Clin Vaccine Immunol; 2012 Mar; 19(3):313-8. PubMed ID: 22219315
[TBL] [Abstract][Full Text] [Related]
11. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
[No Abstract] [Full Text] [Related]
12. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.
Van der Vliet D; Pepin S; Lambert M; Fauchoux N; Donazzolo Y; Dupuy M; Dakowski C; Denis M
Hum Vaccin; 2010 Oct; 6(10):823-8. PubMed ID: 20935517
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
Vajo Z; Tamas F; Sinka L; Jankovics I
Lancet; 2010 Jan; 375(9708):49-55. PubMed ID: 20018367
[TBL] [Abstract][Full Text] [Related]
15. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
16. A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults.
Loebermann M; Fritzsche C; Geerdes-Fenge H; Heijnen E; Kirby D; Reisinger EC
Infection; 2019 Feb; 47(1):105-109. PubMed ID: 30298473
[TBL] [Abstract][Full Text] [Related]
17. Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.
Song JY; Cheong HJ; Lee J; Wie SH; Park KH; Kee SY; Jeong HW; Kim YS; Noh JY; Choi WS; Park DW; Sohn JW; Kim WJ
Hum Vaccin Immunother; 2014; 10(10):2958-64. PubMed ID: 25483462
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.
Kang K; Han S; Hong T; Jeon S; Paek J; Kang JH; Yim DS
Yonsei Med J; 2016 Nov; 57(6):1354-60. PubMed ID: 27593862
[TBL] [Abstract][Full Text] [Related]
19. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults.
Anh DD; Thiem VD; Anh NTH; Huong VM; Nga NT; Thang TC; Thai DH; Chien VC; Holt R; Wahid R; Flores J; Berlanda Scorza F; Taylor DN
Vaccine; 2016 Oct; 34(45):5457-5462. PubMed ID: 27567493
[TBL] [Abstract][Full Text] [Related]
20. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina M; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Health Technol Assess; 2010 Dec; 14(55):193-334. PubMed ID: 21208550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
